• Skip to content
  • Skip to primary sidebar

Davis+Gilbert LLP

From our base in New York, we represent a diverse range of clients across the country and around the world.

  • People
  • Services
  • Emerging Issues

Disease Efficacy

The FTC’s “Reasonable Basis” Standard Has Evolved for Disease Efficacy Claims

January 9, 2019 by Megan O'Malley

The Bottom Line The FTC made it clear many times in 2018 that disease efficacy claims must be supported by competent and reliable scientific evidence, including human clinical testing, and that expert opinions will help guide the kind of human clinical testing and the number of RCTs that is Continue Reading

Alert - January 9, 2019

Primary Sidebar

  • Sitemap
  • Privacy Policy
  • Terms and Conditions
  • Accessibility Statement
  • About Us
  • Location
  • Subscribe
© 2025 Copyright Davis+Gilbert LLP. Attorney Advertising.
  • People
  • Services
  • Emerging Issues
  • Insights + Events
  • Culture + Community
  • Pro Bono + Corporate Social Responsibility
  • Careers
  • About Us
  • Subscribe
  • Location
This site uses cookies to store information on your device. These cookies either support essential functions of the site or are used to develop analytics regarding usage of our site. Click Accept to continue using the site with our recommended settings or click Decline to disable non-essential cookies.AcceptDecline